Cañamares Orbis, I. Cortijo Cascajares, Susana Ferrari Piquero, José Miguel García Muñoz, C Goyache Goñi, María del Puy
Lapatinib en combinación con trastuzumab en el tratamiento del cáncer de mama metastásico HER2 positivo: Experiencia de uso. [artículo] - Farmacia hospitalaria: órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria, 2014 - 38(2):130-4.
Formato Vancouver:
García-Muñoz C, Cortijo-Cascajares S, Cañamares-Orbis I, Goyache-Goñi MP, Ferrari-Piquero JM. Lapatinib en combinación con trastuzumab en el tratamiento del cáncer de mama metastásico HER2 positivo: Experiencia de uso. Farm Hosp. 2014 Apr 1;38(2):130-4.
PMID: 24669898
Contiene 9 referencias
Objective: To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer.
Method: Retrospective observational study. Patients treated with Trastuzumab and Lapatinib between January of 2010 and May of 2012 were selected. Demographical and clinical data were gathered.
Results: 23 patients with metastatic breast cancer (mean age 59.3 ± 13.3 years) were included. All of them had received an average of 5 treatment lines with at least one of them including Trastuzumab. The median progression-free survival rate with combined Lapatinib + Trastuzumab, with or without associated chemotherapy was 7 months (95% CI: 2.78-11.21) and 3 months for the patients only receiving Lapatinib and Trastuzumab. Seven patients experienced adverse events and in four patients the treatment was stopped due to toxicity.
Conclusions: The treatment with HER2-receptor inhibitors in our patients resulted in progression-free survival rates similar to those published in clinical trials with patients receiving Lapatinib + Trastuzumab not combined with any other anti-cancer therapy, with good treatment tolerability.
Lapatinib en combinación con trastuzumab en el tratamiento del cáncer de mama metastásico HER2 positivo: Experiencia de uso. [artículo] - Farmacia hospitalaria: órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria, 2014 - 38(2):130-4.
Formato Vancouver:
García-Muñoz C, Cortijo-Cascajares S, Cañamares-Orbis I, Goyache-Goñi MP, Ferrari-Piquero JM. Lapatinib en combinación con trastuzumab en el tratamiento del cáncer de mama metastásico HER2 positivo: Experiencia de uso. Farm Hosp. 2014 Apr 1;38(2):130-4.
PMID: 24669898
Contiene 9 referencias
Objective: To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer.
Method: Retrospective observational study. Patients treated with Trastuzumab and Lapatinib between January of 2010 and May of 2012 were selected. Demographical and clinical data were gathered.
Results: 23 patients with metastatic breast cancer (mean age 59.3 ± 13.3 years) were included. All of them had received an average of 5 treatment lines with at least one of them including Trastuzumab. The median progression-free survival rate with combined Lapatinib + Trastuzumab, with or without associated chemotherapy was 7 months (95% CI: 2.78-11.21) and 3 months for the patients only receiving Lapatinib and Trastuzumab. Seven patients experienced adverse events and in four patients the treatment was stopped due to toxicity.
Conclusions: The treatment with HER2-receptor inhibitors in our patients resulted in progression-free survival rates similar to those published in clinical trials with patients receiving Lapatinib + Trastuzumab not combined with any other anti-cancer therapy, with good treatment tolerability.
